Updated systematic literature review and network meta-analysis of cladribine tablets versus currently approved disease-modifying treatments for active relapsing-remitting multiple sclerosis.

Gerard T Harty¹, Michelle Jones², Vikalp Maheshwari³, J Saipriya³

¹Merck Healthcare KGaA, Frankfurter Str. 250, Darmstadt 64293, Germany.

²Merck Serono (Ireland) Ltd, an affiliate of Merck KGaA, 4045 Kingswood Rd, Brownsbarn, Dublin, Ireland. Electronic address: michelle.jones@merckgroup.com.

³Parexel International, Northwick Park Hospital, Watford Road, Harrow HA1 3UJ, United Kingdom.

PubMed DOI

Abstract

BACKGROUND: To update previous work assessing the relative efficacy and safety of cladribine tablets compared to currently approved disease-modifying treatments (DMTs) in patients with active relapsing-remitting multiple sclerosis (RRMS), using systematic literature review (SLR) and network meta-analysis (NMA). METHODS: Systematic literature searches were conducted in MEDLINE, Embase, MEDLINE In-…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.